Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Suravi Raychaudhuri, Ted A. Gooley, Allegra Rasmussen, Kim Quach, Eva Gill, Anna B. Halpern, Jacob S. Appelbaum, Cristina M. Ghiuzeli, Paul C. Hendrie, Ryan D. Cassaday, Roland B. Walter, Mary-Elizabeth M. Percival

Blood Neoplasia (2025) 2 (3): 100085.

https://doi.org/10.1016/j.bneo.2025.100085

Published: 2025

Includes: Supplemental data

Journal Articles

TYK2 is essential for the therapeutic effect of IFN-α in Jak2 V617F-induced murine myeloproliferative neoplasms

Blood Neoplasia (2025) 2 (3): 100087.

https://doi.org/10.1016/j.bneo.2025.100087

Published: 2025

Includes: Supplemental data

Journal Articles

Quality of life, fatigue, depression, attention deficits, and pain after childhood Langerhans cell histiocytosis

Malin Sveijer, Désirée Gavhed, Helena Hertzberg, Eric Zander, Jan-Inge Henter, Tatiana von Bahr Greenwood

Blood Neoplasia (2025) 2 (3): 100098.

https://doi.org/10.1016/j.bneo.2025.100098

Published: 2025

Includes: Supplemental data

Journal Articles

Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions

Tamara Westover, Michael P. Walsh, Sherif Abdelhamed, Emily Xiong, Jing Ma, Guangchun Song, Melvin E. Thomas, III, Masayuki Umeda, Jamie L. Maciaszek, Jasmine C. Wong, Astrid Wintering, Lu Wang, Peter D. Emanuel, Mignon L. Loh, Sarah K. Tasian, Elliot Stieglitz, Jason R. Schwartz, Kevin M. Shannon, Jeffery M. Klco

Blood Neoplasia (2025) 2 (2): 100093.

https://doi.org/10.1016/j.bneo.2025.100093

Published: 2025

Includes: Supplemental data

Journal Articles

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms

Blood Neoplasia (2025) 2 (2): 100089.

https://doi.org/10.1016/j.bneo.2025.100089

Published: 2025

Includes: Supplemental data

Journal Articles

Multiplex gene editing models of del(7q) reveal combined CUX1 and EZH2 loss drives clonal expansion and drug resistance

Matthew R. M. Jotte, Angela Stoddart, Tanner C. Martinez, Raven Moten, Yuqing Xue, Molly K. Imgruet, Hunter Blaylock, Henna S. Nam, Bonnie Hu, Jermaine Austin, Ningfei An, Saira Khan, Sandeep K. Gurbuxani, Megan E. McNerney

Blood Neoplasia (2025) 2 (2): 100083.

https://doi.org/10.1016/j.bneo.2025.100083

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood Neoplasia (2025) 2 (2): 100082.

https://doi.org/10.1016/j.bneo.2025.100082

Published: 2025

Includes: Supplemental data

Journal Articles

Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United States

Ming S. Lee, Rebecca E. Kaiser, Christopher D. Armstrong, David B. Dukenik, Nancy S. Elliott, Raymond R. Balise, Justin M. Watts, Mikkael A. Sekeres, Erin N. Kobetz, Justin Taylor

Blood Neoplasia (2025) 2 (2): 100078.

https://doi.org/10.1016/j.bneo.2025.100078

Published: 2025

Journal Articles

A novel 3-way translocation involving ETV6 :: IL3 drives AML with eosinophilia

Blood Neoplasia (2025) 2 (2): 100079.

https://doi.org/10.1016/j.bneo.2025.100079

Published: 2025

Includes: Supplemental data

Journal Articles

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms

Astrid G. S. van Halteren, Paul G. Kemps, Jelske Forma-Borst, Yanling Xiao, Maud A. J. I. van den Oetelaar, Nina U. Gelineau, Robert M. Verdijk, Lydia E. Vos, Koen D. Quint, Cor van den Bos, Eli L. Diamond, Jan A. M. van Laar

Blood Neoplasia (2025) 2 (2): 100074.

https://doi.org/10.1016/j.bneo.2025.100074

Published: 2025

Includes: Supplemental data

Journal Articles

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes

Blood Neoplasia (2025) 2 (2): 100068.

https://doi.org/10.1016/j.bneo.2025.100068

Published: 2025

Includes: Supplemental data

Journal Articles

Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis

Nathalie Loeb, Olivia Katsnelson, Anshika Jain, Parsa Tahvildar, Daniel Teitelbaum, Alejandro Garcia-Horton

Blood Neoplasia (2025) 2 (2): 100070.

https://doi.org/10.1016/j.bneo.2025.100070

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm

Zhuoer Xie, Najla Al Ali, Ling Zhang, Peter Papenhausen, Virginia Olivia Volpe, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Alison Walker, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood Neoplasia (2025) 2 (2): 100062.

https://doi.org/10.1016/j.bneo.2024.100062

Published: 2025

Includes: Supplemental data

Journal Articles

New leads to enhance tagraxofusp efficacy in pDC-AML

Morgane Boichut, Margaux Poussard, Xavier Roussel, Imane Belakri, Sabeha Biichlé, Maxime Fredon, Florian Renosi, Romain Boidot, Olivier Adotevi, Christopher Brooks, Francine Garnache-Ottou, Fanny Angelot Delettre

Blood Neoplasia (2025) 2 (2): 100066.

https://doi.org/10.1016/j.bneo.2025.100066

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal composition of karyotypically normal AML at diagnosis is not affected by the microenvironment

Monika M. Toma, Adam Karami, Margaret Nieborowska-Skorska, Tomasz Skorski

Blood Neoplasia (2025) 2 (2): 100073.

https://doi.org/10.1016/j.bneo.2025.100073

Published: 2025

Journal Articles

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia

Kuo-Kai Chin, Yannis Valtis, Andriy Derkach, Meira Yisraeli Salman, Leora Boussi, Jenna Ciervo, Mark B. Geyer, Jae H. Park, Martin S. Tallman, Jacob L. Glass, Aaron D. Goldberg, Eytan M. Stein

Blood Neoplasia (2024) 1 (4): 100038.

https://doi.org/10.1016/j.bneo.2024.100038

Published: 2024

Includes: Supplemental data

Journal Articles

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

Ella Troy, Joseph Caporale, Yasemin Sezgin, Marcelo S. F. Pereira, Gregory Behbehani, Justin Lyberger, Dean A. Lee, Meisam Naeimi Kararoudi

Blood Neoplasia (2024) 1 (4): 100032.

https://doi.org/10.1016/j.bneo.2024.100032

Published: 2024

Includes: Supplemental data

Journal Articles

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium

Blood Neoplasia (2024) 1 (3): 100023.

https://doi.org/10.1016/j.bneo.2024.100023

Published: 2024

Includes: Supplemental data

Journal Articles

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

Blood Neoplasia (2024) 1 (3): 100027.

https://doi.org/10.1016/j.bneo.2024.100027

Published: 2024

Includes: Supplemental data

Journal Articles

Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study

Amy E. DeZern, Johannes B. Goll, Travis L. Jensen, Sridhar Nonavinkere Srivatsan, Nancy K. Gillis, Gregory A. Abel, Eric Padron, H. Joachim Deeg, Tareq Al Baghdadi, Jane Jijun Liu, Rami S. Komrokji, Steven D. Gore, Wael Saber, Rafael Bejar, Matthew J. Walter, R. Coleman Lindsley, Seth Sherman, Nancy DiFronzo, Mikkael A. Sekeres

Blood Neoplasia (2024) 1 (3): 100026.

https://doi.org/10.1016/j.bneo.2024.100026

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

TYK2 is essential for the therapeutic effect of IFN-α in Jak2 V617F-induced murine myeloproliferative neoplasms

Quality of life, fatigue, depression, attention deficits, and pain after childhood Langerhans cell histiocytosis

Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms

Multiplex gene editing models of del(7q) reveal combined CUX1 and EZH2 loss drives clonal expansion and drug resistance

Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United States

A novel 3-way translocation involving ETV6 :: IL3 drives AML with eosinophilia

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes

Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm

New leads to enhance tagraxofusp efficacy in pDC-AML

Clonal composition of karyotypically normal AML at diagnosis is not affected by the microenvironment

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only